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Central message: non-inferiority trials need thorough understanding of statistical and technical 19 
peculiarities as to have a valuable clinical impact.  20 
 21 
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There are three main types of clinical trials based on the statistical hypothesis tested. “Superiority” 39 
trials compare two treatments to determine which is better;  “equivalence” trials test whether a new 40 
treatment is as effective as the standard treatment; “non-inferiority” trials have the aim to demonstrate 41 
that a new experimental treatment is not unacceptably worse than the standard treatment. These latter 42 
studies are being more and more embraced [1] because they allow to study new treatments which can 43 
bring an advantage in terms of costs, patient’s compliance to medication, fewer adverse effects or 44 
greater availability [2].  45 
In this issue, Falk and Friede focus on the main aspects of non-inferiority trials with prodigious 46 
attention to details [3]. The authors describe the critical step of choosing a non-inferiority margin, 47 
that is the value which the effect measure of the experimental treatment must not exceed when 48 
compared to the standard treatment to prove its non-inferiority. The non-inferiority margin should be 49 
oriented from both a statistical and a clinical point of view and should be prospectively calculated 50 
and clearly reported in the protocol of the study [4]. Once the non-inferiority margin is set, the trial 51 
null hypothesis will test that the treatment difference between the standard and the experimental 52 
strategy is equal or greater than the assumed margin while the alternative hypothesis will state that 53 
the efficacy value of the standard treatment and the experimental treatment differ by no more than 54 
the margin. It is important to acknowledge the different statistical hypothesis which are being tested 55 
in superiority and inferiority trials in order to interpret results accordingly. In a superiority trial the 56 
acceptance of the null hypothesis, that tests if the new treatment is not superior to the standard one, 57 
does not allow us to draw a conclusion of non-inferiority because this would lead to a biased estimate. 58 
Conversely, in a non-inferiority trial when the null hypothesis is rejected, we assume that the new 59 
treatment is non-inferior to the comparator and that the two treatments only differ by clinically 60 
irrelevant effects.  61 
But what does clinically irrelevant mean for our patients? A practical example may help. Would you 62 
accept to buy a house located in a less safe neighborhood just because it is less expensive than another 63 
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one in a safer area? If the difference in the crime rate were only of 0.1%, it would be reasonable to 64 
save 10% on the cost of the house, but if the saving were 0.1% and the crimes rate were 10% higher 65 
it would be hard to fairly choose the cheapest house. This applies to our patients in our daily practice. 66 
As suggested by the European Medicines Agency [4], there are areas where mortality or other 67 
irreversible morbidities (e.g. stroke) may not allow any margin of inferiority. It would be of extreme 68 
difficulty to ethically accept the excess rate in deaths to compare a new treatment just because it is 69 
less expensive or with minor adverse effects. For example, a quater in die drug A has proved over 70 
decades to be safe and efficient in preventing death, stroke and myocardial infarction. A new quaque 71 
die treatment B would be positively accepted for its anticipated better compliance to treatment as long 72 
as it will not cause more deaths, strokes and myocardial infarctions than drug A. Here comes an 73 
intriguing paradox: if we assume that drug B will increase the compliance to the treatment, we can 74 
reasonably anticipate that there will be a relevant advantage which translates into a superior outcome 75 
and goes beyond the pure evidence of having only a more comfortable regimen for the patient. So 76 
non-inferiority is being tested when superiority could be proved.  77 
Concluding,  non-inferiority trials can represent a rigorous method to widen treatment options in 78 
proper settings, but physicians should carefully read and understand the deepest statistical and 79 
technical pieces of them in order to verify that a proper non-inferiority margin was chosen and assess 80 
the extent of the clinically irrelevant events.  81 
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